Facing the price competition from India in the field of generic drug intermediates, Chinese enterprises have turned to high-tech barrier products in search of breakthroughs. For instance, Shengnuo Biotech focuses on GLP-1 weight loss drug intermediates, and the cost competitiveness of its semaglutide intermediate ranks among the top three globally. Nuotai Biotech has reduced costs by 28% through large-bag packaging technology and has tied up with international giants such as Eli Lilly and Novo Nordisk. Industry data shows that Chinese enterprises have seen significant growth in niche fields such as peptides and ADC drug linkers, with overseas revenue accounting for over 60%. In addition, the RCEP agreement offers new opportunities for regional cooperation in the Asia-Pacific region, and China's production capacity is accelerating its transfer to the Southeast Asian market.